Real-World safety of ofev monitored in 425 lung disease patients
NCT ID NCT04559581
First seen Feb 06, 2026 · Last updated May 07, 2026 · Updated 10 times
Summary
This study looked at the safety of the drug Ofev in 425 people in Japan with a type of lung disease that gets worse over time (progressive fibrosing interstitial lung disease). The main goal was to track any side effects, especially liver problems. Participants had not taken Ofev before and were followed in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG DISEASES, INTERSTITIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, 1416017, Japan
Conditions
Explore the condition pages connected to this study.